Clinical utility of circulating tumor DNA for colorectal cancer
-
- Hiroki Osumi
- Department of Gastroenterology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan
-
- Eiji Shinozaki
- Department of Gastroenterology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan
-
- Kensei Yamaguchi
- Department of Gastroenterology Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan
-
- Hitoshi Zembutsu
- Cancer Precision Medicine Center Cancer Institute Japanese Foundation for Cancer Research Tokyo Japan
書誌事項
- 公開日
- 2019-03-04
- 資源種別
- journal article
- 権利情報
-
- http://creativecommons.org/licenses/by-nc-nd/4.0/
- DOI
-
- 10.1111/cas.13972
- 公開者
- Wiley
この論文をさがす
説明
<jats:p>Colorectal cancer (CRC) is currently the most common type of cancer in Japan, and its prognosis has improved because of development of diagnosis and advancement in treatments including surgery and chemotherapy. However, because of intratumor heterogeneity and clonal evolution, tumors often develop resistance to treatment. Genotyping tumor tissue in search of somatic genetic alterations for actionable information has become routine examination in clinical practice. However, the inherent molecular heterogeneity of metastatic tumors and the ability of cancer genomes to dynamically evolve are not properly captured by tissue specimens only. Circulating tumor DNA (ctDNA) carrying tumor‐specific genetic or epigenetic alterations is released into the circulation from tumor cells undergoing apoptosis or necrosis. Analysis of ctDNA has the potential to change clinical practice by exploiting blood rather than tissue, as a source of information. Here, we provide an overview of the characteristics of ctDNA and focus on detection methods for ctDNA, and the feasibility of use of ctDNA to monitor tumor dynamics for patients with colorectal cancer.</jats:p>
収録刊行物
-
- Cancer Science
-
Cancer Science 110 (4), 1148-1155, 2019-03-04
Wiley
